David Allison

So that's what I would look at at the public health level in what we think of as traditional public health.

Now, with the GLP-1 agonist-related drugs and some other drugs being as profoundly beneficial as they appear to be, I think we're going to get to the point where it's going to be hard.

I think we're already asking the question, and I think it's going to be hard not to take the question seriously of, should it almost be the default?

That is just like we've asked the question, and people give different answers, but we asked the question, should it be that the default is you get this vaccine when you're a kid?

That you get your teeth fluoridated at the dentist?

That it's not, hmm, maybe some people should get that.

I think we are at the point where we're saying, as these drugs continue to be tested and experienced, if we continue to see the effects we're getting, are we getting to the point where we should start to say, you know what, that idea of the polypill that came up decades ago where young adults, even if you don't have diabetes, obesity, hypertension, et cetera, you'd get a low-dose diuretic.

low-dose metformin, et cetera, low-dose statin.

Are we at the point where we probably still should do that and then say, anybody get a low-dose GLP-1 agonist-related drug and we'll roll it out and we'll pay for it and anybody in the country who wants it can get it or almost anybody?

I think that may be the future.